-
Product Insights
NewNet Present Value Model: BioCardia Inc’s CardiAMP
Empower your strategies with our Net Present Value Model: BioCardia Inc's CardiAMP report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Celcuity Inc’s Gedatolisib
Empower your strategies with our Net Present Value Model: Celcuity Inc's Gedatolisib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CardiAMP in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CardiAMP in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CardiAMP in Systolic Heart Failure Drug Details: CardiAMP is under development...
-
Product Insights
Myocardial Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Ischemia - Drugs In Development, 2023’, provides an overview of the Myocardial Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Systolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Systolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Systolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorasidenib Citrate in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorasidenib Citrate in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorasidenib Citrate in Low-Grade Glioma Drug Details: Vorasidenib (AG-881) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cardiamp in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cardiamp in Systolic Heart Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CardiAMP in Systolic Heart Failure Drug Details: CardiAMP is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CardiALLO in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CardiALLO in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CardiALLO in Systolic Heart Failure Drug Details: CardiALLO is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0317 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Ovarian Cancer Drug Details:MP-0317 is under development for the treatment of...
-
Sector Analysis
Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 7MM was valued at $31.9 billion in 2022 and is expected to achieve a CAGR of more than 5% during 2022-2032. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData expects uptake of SGLT2 inhibitors and three first-in-class drugs to be the strongest driver of the total heart failure markets in the 7MM. Heart Failure Market Outlook, 2022-2032 ($ Billion) Buy...